Milwaukee, WI, United States
Milwaukee, WI, United States

The Medical College of Wisconsin, or simply MCW, is a private, freestanding medical school and graduate school of science located in Milwaukee, Wisconsin. It was formerly affiliated with Marquette University, but has operated as an independent institution since 1967. MCW is accredited by the Higher Learning Commission of the North Central Association of Colleges and Schools and by the Liaison Committee on Medical Education . The NCA is the accrediting body for all institutions of higher education in the College's geographic region and the LCME is the accrediting body of all US medical schools. Along with the University of Wisconsin School of Medicine and Public Health, it is one of only two medical schools in Wisconsin, and it is the only private medical school in the state.More than 1,350 faculty physicians with MCW provide adult and pediatric care to more than 425,000 patients, representing more than 1.6 million patient visits annually. Wikipedia.


Time filter

Source Type

Patent
Medical College of Wisconsin | Date: 2016-11-11

An esophageal device is used to recognize, diagnose, characterize, or relieve an impact of an abnormal or defective UES anatomy, physiology, or functionality. In one implementation, the esophageal device measures a UES response to esophageal fluid infusion to detect or characterize an abnormality or defective UES anatomy, physiology, or functionality. An Upper Esophageal Sphincter compression device is used to increase intra-luminal pressure within the Upper Esophageal Sphincter of a patient in order relieve an impact of an abnormal or defective UES anatomy, physiology, or functionality.


Patent
Bolder Biotechnology, Inc., Indiana University and Medical College of Wisconsin | Date: 2016-09-19

Methods and compositions comprising hematopoietic growth factor proteins and/or protein analogs thereof and/or combinations thereof and angiotensin converting enzyme inhibitors to treat the acute and long term adverse effects of radiation exposure in subjects who have been or will be exposed to radiation are disclosed.


Patent
Wisconsin Alumni Research Foundation and Medical College of Wisconsin | Date: 2016-10-31

Described herein are methods of predicting the risk of developing ovarian cancer recurrence of a subject comprising the steps of detecting the expression levels of at least four of the six genes selected from the group consisting of AKT2, KRAS, RAC1, CALM3, RPS6KA2 and YWHAB or the gene products thereof, wherein the presence of increased expression levels of the genes or the gene products is predictive of the increased risk of developing ovarian cancer recurrence in the subject. Kits for practicing the methods are also disclosed.


Patent
The Queens Medical Center, The University Of Hawaii, Medical College of Wisconsin and INC Research | Date: 2017-01-18

This invention relates to a system that adaptively compensates for subject motion in real-time in an imaging system. An object orientation marker (30), preferably a retro-grate reflector (RGR), is placed on the head or other body organ of interest of a patient (P) during a scan, such as an MRI scan. The marker (30) makes it possible to measure the six degrees of freedom (x, y, and z-translations, and pitch, yaw, and roll), or pose, required to track motion of the organ of interest. A detector, preferably a camera (40), observes the marker (30) and continuously extracts its pose. The pose from the camera (40) is sent to the scanner (120) via an RGR processing computer (50) and a scanner control and processing computer (100), allowing for continuous correction of scan planes and position (in real-time) for motion of the patient (P). This invention also provides for internal calibration and for co-registration over time of the scanners and tracking systems reference frames to compensate for drift and other inaccuracies that may arise over time.


(PR NewsChannel) / May 5, 2017 / San Francisco, California Lucia R. Tuffanelli, MD, FAAD, Dermatologist currently serving patients within her practice, Epstein & Tuffanelli MDs Inc. and affiliated with St. Francis Hospital and California Pacific Medical Center, has been named a 2017 Top Doctor in San Francisco, California. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care. Dr. Lucia R. Tuffanelli’s career in medicine began in 1982 when she graduated from the Medical College of Wisconsin. Upon receiving her medical degree, she completed an internal medicine internship and residency at Martinez Veterans Hospital, before undertaking an additional residency in dermatology at the State University of New York, Brooklyn Health and Science Center. To stay current in her field, Dr. Tuffanelli maintains professional memberships with the American Medical Association, the American Academy of Dermatology, the California Medical Society, the Women’s Dermatological Society, the Pacific Dermatology Association, the Wilderness Medicine Society, and the San Francisco Medical Society, where she has served on the Committee for Physician Well Being since 2000. Dr. Tuffanelli is certified by the American Board of Dermatology, and she treats a wide range of conditions relating to the skin for patients of all ages. Conditions treated by her include eczema, boils, dermatitis, hives, rosea, varicose veins, parapsoriasis, and folliculitis, as well as injuries caused by burns including sunburn. Expert procedures undertaken by Dr. Tuffanelli range from skin tag removal, to cyst incision and drainage, and acne surgery. She is dedicated to treating pediatric and adult medical dermatologic problems and wound care, as well as skin cancer exams and prevention. In addition to her clinical practice, Dr. Tuffanelli serves as Adjuvant Professor at Touro University in Vallejo, California, and volunteers at the University of California, San Francisco. She has also volunteered with, and dedicated her time to the Himalayan Health Exchange – medical expedition. With her wealth of experience and reputation for clinical excellence, Dr. Tuffanelli is a dermatologist in high demand, and yet she still finds time to help and advise less experienced colleagues when needed. Her dedication, expertise and commitment to her specialty and patients makes Dr. Lucia R. Tuffanelli a very worthy winner of a 2017 Top Doctor Award. About Top Doctor Awards Top Doctor Awards specializes in recognizing and commemorating the achievements of today’s most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.


Amirkhanian Y.A.,Medical College of Wisconsin
Current HIV/AIDS Reports | Year: 2014

Worldwide, men who have sex with men (MSM) remain one of the most HIV-vulnerable community populations. A global public health priority is developing new methods of reaching MSM, understanding HIV transmission patterns, and intervening to reduce their risk. Increased attention is being given to the role that MSM networks play in HIV epidemiology. This review of MSM network research studies demonstrates that: (1) Members of the same social network often share similar norms, attitudes, and HIV risk behavior levels; (2) Network interventions are feasible and powerful for reducing unprotected sex and potentially for increasing HIV testing uptake; (3) HIV vulnerability among African American MSM increases when an individual enters a high-risk sexual network characterized by high density and racial homogeneity; and (4) Networks are primary sources of social support for MSM, particularly for those living with HIV, with greater support predicting higher care uptake and adherence. © 2014 Springer Science+Business Media.


Turaga K.K.,Medical College of Wisconsin | Kvols L.K.,H. Lee Moffitt Cancer Center and Research Institute
CA Cancer Journal for Clinicians | Year: 2011

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are relatively rare tumors that arise from the diffuse neuroendocrine system. This heterogeneous group of tumors was often considered a single entity. This belied their biological diversity, and the biggest advance in understanding these tumors over the past decades has been in understanding this diversity. Diagnosis of these tumors has been aided by advances in pathological diagnosis and classification and tumor imaging with endoscopic ultrasound and somatostatin receptor fusion imaging. Genetic and molecular advances have identified molecular targets in the treatment of these tumors. Surgery remains the mainstay of treatment, amply supported by interventional radiological techniques, including embolization. Treatment of metastatic disease has improved significantly with the addition of several new agents, including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and yttrium-90-DOTA (1,4,7,10-tetraazacyclododecane-1,4,7, 10-tetraacetic acid) and lutetium-177-DOTA octreotate. Despite significant advances in the understanding and management of GEP-NETs, the survival of patients remains largely unchanged and there remains a need for the development of national and international research collaborations to spearhead future efforts. © 2011 American Cancer Society, Inc.


Imig J.D.,Medical College of Wisconsin
Physiological Reviews | Year: 2012

Epoxyeicosatrienoic acids (EETs) are arachidonic acid metabolites that importantly contribute to vascular and cardiac physiology. The contribution of EETs to vascular and cardiac function is further influenced by soluble epoxide hydrolase (sEH) that degrades EETs to diols. Vascular actions of EETs include dilation and angiogenesis. EETs also decrease inflammation and platelet aggregation and in general act to maintain vascular homeostasis. Myocyte contraction and increased coronary blood flow are the two primary EET actions in the heart. EET cell signaling mechanisms are tissue and organ specific and provide significant evidence for the existence of EET receptors. Additionally, pharmacological and genetic manipulations of EETs and sEH have demonstrated a contribution for this metabolic pathway to cardiovascular diseases. Given the impact of EETs to cardiovascular physiology, there is emerging evidence that development of EET-based therapeutics will be beneficial for cardiovascular diseases. © 2012 by the American Physiological Society.


Salzman N.H.,Medical College of Wisconsin
Current Opinion in Microbiology | Year: 2011

An estimated 100 trillion microbes colonize human beings, with the majority of organisms residing in the intestines. This microbiota impacts host nutrition, protection, and gut development. Alterations in microbiota composition are associated with susceptibility to various infectious and inflammatory gut diseases. The mucosal surface is not a static barrier that simply prevents microbial invasion but a critical interface for microbiota-immune system interactions. Recent work suggests that dynamic interactions between microbes and the host immune system at the mucosal surface inform immune responses both locally and systemically. This review focuses on intestinal microbiota-immune interactions leading to intestinal homeostasis, and show that these interactions at the GI mucosal surface are critical for driving both protective and pathological immune responses systemically. © 2010 Elsevier Ltd.


Hillard C.J.,Medical College of Wisconsin
Seminars in Immunology | Year: 2014

The CB1 cannabinoid receptor is a G protein coupled receptor that is widely expressed throughout the brain. The endogenous ligands for the CB1 receptor (endocannabinoids) are N-arachidonylethanolamine and 2-arachidonoylglycerol; together the endocannabinoids and CB1R subserve activity dependent, retrograde inhibition of neurotransmitter release in the brain. Deficiency of CB1 receptor signaling is associated with anhedonia, anxiety, and persistence of negative memories. CB1 receptor-endocannabinoid signaling is activated by stress and functions to buffer or dampen the behavioral and endocrine effects of acute stress. Its role in regulation of neuronal responses is more complex. Chronic variable stress exposure reduces endocannabinoid-CB1 receptor signaling and it is hypothesized that the resultant deficiency in endocannabinoid signaling contributes to the negative consequences of chronic stress. On the other hand, repeated exposure to the same stress can sensitize CB1 receptor signaling, resulting in dampening of the stress response. Data are reviewed that support the hypothesis that CB1 receptor signaling is stress responsive and that maintaining robust endocannabinoid/CB1 receptor signaling provides resilience against the development of stress-related pathologies. © 2014 Elsevier Ltd.

Loading Medical College of Wisconsin collaborators
Loading Medical College of Wisconsin collaborators